the trial of preventing hypertension (trophy) trophy
TRANSCRIPT
![Page 1: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/1.jpg)
The TRial Of Preventing HYpertension (TROPHY)
TROPHY
![Page 2: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/2.jpg)
TROPHY – hypothesis
The TRial Of Preventing HYpertension (TROPHY) is an investigator-initiated trial to examine whether early treatment of high-normal blood pressure values (according to JNC VI) with candesartan would prevent or postpone the development of stage 1 hypertension.
Julius et al, Hypertension 2004
![Page 3: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/3.jpg)
TROPHY – objectives
• Primary– to determine whether treatment with candesartan
16 mg compared with placebo reduces the incidence of hypertension in subjects with high-normal BP
• Secondary– evaluate reduction of BP after 2 years of treatment
with candesartan 16 mg versus placebo – evaluate incidence of hypertension after 2 years of
treatment with candesartan 16 mg versus placebo– evaluate quality of life during 2 years of treatment
with candesartan 16 mg versus placebo
Julius et al, Hypertension 2004
![Page 4: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/4.jpg)
TROPHY– inclusion criteria
• Aged 30 to 65 years
• Clinic BP reading of 130-139/ 89 mm Hg or 139/85-89 mm Hg
Julius et al, Hypertension 2004
![Page 5: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/5.jpg)
TROPHY – study design
Two Years Two Years
Qualifying period*
Placebo
Non-pharmacological treatment
Non-pharmacological treatment
Candesartan cilexetil16 mg
n 400
n 400
Placebo
Placebo
*Clinic BP reading of 130-139/ 89 mm Hgor 139/85-89 mm Hg
Julius et al, Hypertension 2004
![Page 6: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/6.jpg)
TROPHY – end point
• Development of clinical hypertension– Mean clinic BP by automated device 140/90 mm
Hg at 3 different clinic visits during the 4-year study period
– Mean clinic BP by automated device 160/100 mm Hg at any single visit during the 4-year study period
– Development of signs of target organ damage or a BP condition requiring pharmacological treatment, as judged by the investigator
– Mean clinic BP by automated device 140/90 mm Hg at the 48-month visit
Julius et al, Hypertension 2004
![Page 7: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/7.jpg)
TROPHY – baseline characteristics
Variable Value
Randomised patients, n 809Male, n 482Female, n 326
Age, years 49 14BMI, kg/m2 30 5Blood pressure, mmHgClinic automated 134 4/85 4Clinic regular 133 5/85 4Measured at home 134 9/83
10 Julius et al, Hypertension 2004
![Page 8: The TRial Of Preventing HYpertension (TROPHY) TROPHY](https://reader036.vdocuments.us/reader036/viewer/2022072015/56649ec05503460f94bcb2b5/html5/thumbnails/8.jpg)
TROPHY: Risk of hypertension after two years with candesartan vs placebo, followed
by two years of placebo vs placebo
Time point
Candesartan,
n
Placebo,
n
Relative risk (95% CI) p
At two 2 years
53 154 66.3 <0.001
At four 4 years
208 240 15.6 <0.007
Julius S et al. N Engl J Med 2006;available at http://www.nejm.org